HMGCR and metabolic syndrome: Randomized controlled studies with a larger number of patients and a longer treatment period may be required for an appropriate analysis of the effect of omega-3 on dyslipidemia in patients receiving long-term treatment with HMG-CoA reductase inhibitors.